GlassScriptPhysician profile
Ashish Trivedi
NPI 1134177413
$116,890.35
in general payments reported to CMS, 2019-2025
71 companies · $3,680 in 2025
The $3,680 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $36K · 2021: $13K · 2022: $11K · 2023: $14K · 2024: $4,079 · 2025: $3,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $9,652 · Travel and Lodging: $1,833 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,021.86 |
| Consulting Fee | $9,652.00 |
| Travel and Lodging | $1,833.34 |
| Education | $140.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38,470.27 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $17,321.01 | 2019-2025 | Ingrezza |
| Emd Serono, INC. | $12,957.73 | 2019-2025 | Mavenclad |
| Celgene Corporation | $12,506.37 | 2019-2025 | Zeposia |
| Sk Life Science, INC. | $6,271.16 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $5,501.49 | 2020-2023 | |
| Neurelis, INC. | $4,100.76 | 2020-2025 | Valtoco |
| Biogen, INC. | $2,360.61 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Abbvie INC. | $1,501.06 | 2021-2025 | Ubrelvy, Qulipta |
| Kyowa Kirin, INC. | $1,421.31 | 2019-2023 | Nourianz, Nourianz |
| Novartis Pharmaceuticals Corporation | $1,355.58 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,276.64 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Genzyme Corporation | $922.84 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $886.50 | 2024-2025 | |
| Lundbeck LLC | $855.00 | 2019-2025 | Rexulti, Vyepti |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $797.66 | 2019-2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $577.44 | 2019-2025 | Nuplazid |
| Acorda Therapeutics, INC | $546.33 | 2019-2023 | Inbrija, Ampyra |
| Ucb, INC. | $533.20 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Amgen INC. | $513.55 | 2019-2025 | Aimovig, Uplizna |
| Amneal Pharmaceuticals LLC | $477.99 | 2019-2025 | Rytary, Ongentys, Crexont |
| Genentech USA, INC. | $450.34 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Csl Behring | $427.95 | 2019-2025 | Hizentra |
| Eisai INC. | $397.06 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $304.34 | 2021-2025 | Xeomin, Inbrija |
| Tg Therapeutics, INC. | $302.49 | 2023-2025 | |
| Pfizer INC. | $287.03 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $272.37 | 2021-2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $232.36 | 2023-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $221.98 | 2023-2025 | Hyqvia |
| Biohaven Pharmaceuticals, INC. | $210.45 | 2021 | |
| Vanda Pharmaceuticals INC. | $171.91 | 2024-2025 | Ponvory |
| Vertical Pharmaceuticals, LLC | $166.87 | 2019-2020 | |
| Argenx US, INC. | $166.60 | 2023-2025 | Vyvgart Hytrulo |
| Sumitomo Pharma America, INC. | $163.92 | 2023 | Aptiom |
| Boston Scientific Corporation | $162.78 | 2019 | |
| Bausch Health US, LLC | $151.50 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $144.66 | 2022-2025 | Onpattro, Amvuttra |
| Supernus Pharmaceuticals, INC. | $142.31 | 2019-2022 | |
| Allergan, INC. | $111.34 | 2020 | |
| Arbor Pharmaceuticals, INC. | $104.37 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $92.11 | 2021-2022 | |
| Banner Life Sciences, LLC | $82.13 | 2021-2024 | |
| Mdd US Operations, LLC | $77.08 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.75 | 2022 | |
| Azurity Pharmaceuticals, INC. | $71.89 | 2023-2025 | Horizant, Horizant |
| Catalyst Pharmaceuticals, INC. | $67.72 | 2020-2023 | Firdapse |
| Ge Healthcare | $65.67 | 2021-2022 | |
| Axsome Therapeutics, INC. | $64.14 | 2023-2025 | Symbravo, Sunosi |
| Janssen Biotech, INC. | $60.21 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $46.16 | 2020-2024 | Dysport |
| Octapharma USA, INC. | $42.39 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Mallinckrodt Enterprises LLC | $35.71 | 2019 | |
| Avion Pharmaceuticals | $35.50 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $32.13 | 2025 | Lumryz |
| Merz North America, INC. | $29.10 | 2020 | |
| Zogenix INC. | $27.64 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $23.74 | 2023 | Relyvrio |
| Upsher-Smith Laboratories LLC | $21.18 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.12 | 2024 | Rexulti |
| Nevro Corp. | $19.49 | 2024 | Senza |
| Zyla Life Sciences, INC. | $16.54 | 2019 | |
| Cala Health, INC. | $16.41 | 2024 | Cala Kiq, Cala Trio |
| Assertio Therapeutics, INC. | $16.23 | 2019 | |
| Strongbridge US INC. | $16.21 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.92 | 2025 | |
| Akcea Therapeutics, INC. | $15.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.70 | 2021 | |
| Ani Pharmaceuticals, INC. | $15.07 | 2024 | Purified Cortrophin Gel |
| Cycle Pharmaceuticals INC | $14.87 | 2025 | Bafiertam |
| Mallinckrodt Hospital Products INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$34,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.